Building Intrinsic Value in Your Medtech Business: The Disciplines That Drive Premium Exits

In advising small and mid-market healthcare and medical technology companies through mergers and acquisitions (M&A), we are consistently asked some version of the same question: “What can I do right now to increase the value of my business before I sell?” It is a powerful question—as long as it is asked two to five years before a transaction rather than two to five months before one.

The answer lies in understanding the difference between market value and intrinsic value. Market value is the price the market will pay at a given moment in time, driven by deal conditions, buyer appetite, and uncontrollable macroeconomic factors. Intrinsic value is the fundamental quality, resilience, and growth potential of a business—and its construction is almost entirely within a company’s control.

MedWorld Advisors’ guiding principle is Value = Strategic Fit + Timing. The timing component reflects market conditions but strategic fit—how compelling and defensible a business is to a buyer—is a function of intrinsic value. Companies that deliberately invest in building intrinsic value do not simply command higher multiples; they attract more buyers, run cleaner processes, and close transactions with fewer post-signing surprises. In today’s medtech M&A market—with $80 billion in estimated deal values last year and increasingly selective acquirers—the spread between premium and average exits has never been wider. 

According to current market data, medtech and digital health platforms sustain elevated EBITDA multiples of 10-fold to 14-fold for profitable growth businesses, with AI-enabled and technology-integrated platforms commanding even higher premiums. The gap between companies at the top and bottom of that range is rarely explained by product innovation alone. More often, it is a reflection of how confidently a buyer can underwrite the business as a concern.

There are six issues CEOs should review and address to ensure their companies are at the top of the enterprise value spread in a future exit. A brief explanation of these issues follow.

1. Operational Excellence (OpEx): There’s a reason that operationally excellent companies consistently trade at the upper end of the valuation range. OpEx is the foundation for intrinsic value. Buyers are not just purchasing revenue; they are purchasing the ability to sustain and grow that revenue once they take ownership. Every operational weakness—whether in manufacturing quality, regulatory compliance, supply chain reliability, or financial reporting—is a risk that a sophisticated acquirer will identify in due diligence and price into an offer.

2. Revenue Quality and the Recurring Revenue Imperative: This is one of the first questions sellers often ask, and for good reason—not all revenue is created equal. When buyers evaluate a medtech company, they are scrutinizing the composition and quality of revenue just as closely as its total size. A company with $20 million in revenue that is predictable, contract-backed, and diversified across customers is a fundamentally different asset than one generating the same top line from a handful of episodic capital equipment transactions.

3. Customer Concentration: Often mentioned as “the silent valuation killer,” a too heavy customer concentration is one of the most common and most preventable sources of valuation discount in small and mid-market medtech. Any single customer generating more than 20% of revenue will trigger a detailed review in any serious due diligence process. Buyers and their lenders understand the loss of a concentrated customer after an acquisition is not merely a revenue event but rather a structural shift in the risk profile of the desired business.

4. Management Team Depth: A company dependent on its founder or a small senior leadership team is a company with a structural concentration risk that is just as real as customer concentration but more personal, and often more difficult for owners to see clearly. Acquirers understand that post-deal performance is driven by the quality and stability of the management team they are inheriting. When that team is thin, they price the risk accordingly. Usually, a buyer who perceives the business as founder-dependent will either apply a discount or structure a transaction with earnout provisions designed to retain the founder’s participation. However, neither outcome is optimal for the seller.

5. Proprietary Data, IP, and Regulatory Assets: In medtech, intellectual property and regulatory clearances are foundational to valuation but the conversation has increasingly expanded to include a third category: proprietary data assets. The companies commanding the highest premiums in today’s M&A market are those that have accumulated structured, clinically relevant data that a buyer cannot easily replicate. As was noted in a previous column on AI readiness, proprietary datasets are emerging as a core component of medtech strategic value.

6. AI and Digital Infrastructure: Surprisingly, these capabilities are no longer significant differentiators. It is “tablestakes.” The pace at which AI and digital capabilities have moved from competitive advantage to acquirer expectation has been remarkable. Strategic buyers and private equity sponsors are now asking pointed questions about AI capabilities in initial conversations, not just in late-stage diligence. Companies that can articulate a coherent, demonstrated AI strategy are positioned for premium outcomes whereas those that cannot are increasingly viewed as incomplete assets.

Medtech owners who are ready to approach value-building systematically should follow a practical framework to obtain the intrinsic value that will positively impact their future enterprise value. For best results, review the following areas:

• Conduct an honest operational audit. Engage the management team and, where appropriate, outside advisors to assess the business against the standards/KPIs that a buyer’s due diligence team will likely assess. Identify gaps in quality systems, financial reporting, IP documentation, and management bench strength before they are identified by the potential buyer.
• Map revenue composition. Understand what percentage of revenue is recurring, contracted, or otherwise predictable, and what percentage is episodic or dependent on a small number of relationships. Set a multi-year target for improving that composition, and build the commercial strategy to achieve it.
• Address customer concentration proactively. If any customer represents more than 20% of revenue, develop a concrete plan to reduce that dependency. This is not about losing the customer; it’s about growing the rest of the base to dilute the concentration. That focus has been highly successful for some of our clients, as the impact is healthy across the organization.
• Invest in the next generation of leadership. Identify the two or three people beneath the senior leadership layer who could run meaningful parts of the business through a transition. Invest in their development, their compensation structures, and their equity participation. It’s important to understand that the less a business needs its leaders to run it, the more intrinsic value that business will create.
• Organize IP and regulatory documentation. Ensure that patent files, regulatory submissions, clearance letters, and freedom-to-operate opinions are complete, current, and accessible. This is foundational due diligence preparation that pays dividends regardless of a transaction’s timing.
• Begin building the AI and data infrastructure now. Even if a formal AI program is years away, the data foundation for that program should currently be under construction. Clean data, structured workflows, and a documented digital roadmap are the building blocks for which acquirers will look.

Medtech companies that achieve premium exits are rarely the ones that began preparing six months before a transaction. They’re the ones that treated value-building as an ongoing operational discipline by investing in quality, management, revenue quality, and data infrastructure with the same rigor they applied to product development and regulatory compliance.

The market rewards this preparation. In the current environment, where strategic acquirers are concentrating capital on the most defensible, scalable, and AI-ready assets, the spread between a premium exit and an average one is not a matter of luck or timing. It is a matter of choices made two, three, and five years before the deal is signed.

Medtech executives or board members with an eye toward a future liquidity event should start building intrinsic value in their respective organizations now. A transaction need not be imminent; buyers who will eventually set valuations are already evaluating companies against the disciplines described in this column. Businesses will undoubtedly be assessed on these criteria, and they must be ready when that evaluation arrives so they can dictate the selling valuation (and prevent an otherwise dictated price).

MORE FROM THESE AUTHORS—The AI Valuation Gap at Exit: Why Medtech Companies Should Not Ignore AI

Florence Joffroy-Black, CM&AA, and Dave Sheppard, CM&AA, are managing partners at MedWorld Advisors, a global M&A advisory firm serving the medical technology and life-science industries. Florence can be reached at [email protected]. Dave can be reached at [email protected].